Eslicarbazepine is a third-generation antiepileptic drug, structurally classified as a voltage-gated sodium channel blocker, used in the management of partial-onset seizures. This category offers a comprehensive… Read more


![Chemical structure of 5-Acetyl-5,11-dihydro-10H-dibenz[b,f]azepin-10-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F28291-63-6-5-Acetyl-511-dihydro-10H-dibenzbfazepin-10-one.png&w=3840&q=75)
![Chemical structure of 5-Carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl propionate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F186694-22-4-5-Carbamoyl-1011-dihydro-5H-dibenzobfazepin-10-yl-propionate.png&w=3840&q=75)



Eslicarbazepine is a third-generation antiepileptic drug, structurally classified as a voltage-gated sodium channel blocker, used in the management of partial-onset seizures. This category offers a comprehensive collection of Eslicarbazepine reference standards, including structurally related compounds, process-related impurities, degradation products, and stable isotope labelled compounds. Pharmaceutical laboratories utilize these materials for critical quality control processes, such as method validation and comprehensive impurity profiling. By employing these standards, researchers can accurately perform forced degradation studies, assess formulation stability, and identify potential synthetic by-products to ensure regulatory compliance with established international safety guidelines. These materials are vital for conducting reliable analytical testing and ensuring the safety and efficacy of the parent drug throughout its development and manufacturing lifecycle.